IgA transcytosis and antigen recognition govern ovarian cancer immunity
Open Access
- 3 February 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature
- Vol. 591 (7850), 464-470
- https://doi.org/10.1038/s41586-020-03144-0
Abstract
Most ovarian cancers are infiltrated by prognostically relevant activated T cells1,2,3, yet exhibit low response rates to immune checkpoint inhibitors4. Memory B cell and plasma cell infiltrates have previously been associated with better outcomes in ovarian cancer5,6, but the nature and functional relevance of these responses are controversial. Here, using 3 independent cohorts that in total comprise 534 patients with high-grade serous ovarian cancer, we show that robust, protective humoral responses are dominated by the production of polyclonal IgA, which binds to polymeric IgA receptors that are universally expressed on ovarian cancer cells. Notably, tumour B-cell-derived IgA redirects myeloid cells against extracellular oncogenic drivers, which causes tumour cell death. In addition, IgA transcytosis through malignant epithelial cells elicits transcriptional changes that antagonize the RAS pathway and sensitize tumour cells to cytolytic killing by T cells, which also contributes to hindering malignant progression. Thus, tumour-antigen-specific and -antigen-independent IgA responses antagonize the growth of ovarian cancer by governing coordinated tumour cell, T cell and B cell responses. These findings provide a platform for identifying targets that are spontaneously recognized by intratumoural B-cell-derived antibodies, and suggest that immunotherapies that augment B cell responses may be more effective than approaches that focus on T cells, particularly for malignancies that are resistant to checkpoint inhibitors.Keywords
This publication has 31 references indexed in Scilit:
- BTN3A1 governs antitumor responses by coordinating αβ and γδ T cellsScience, 2020
- Tertiary lymphoid structures in the era of cancer immunotherapyNature Reviews Cancer, 2019
- Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockadeGynecologic Oncology, 2018
- A Strong B-cell Response Is Part of the Immune Landscape in Human High-Grade Serous Ovarian MetastasesClinical Cancer Research, 2017
- Tumor-Infiltrating Plasma Cells Are Associated with Tertiary Lymphoid Structures, Cytolytic T-Cell Responses, and Superior Prognosis in Ovarian CancerClinical Cancer Research, 2016
- Intraepithelial CD8+tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancerProceedings of the National Academy of Sciences, 2005
- Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survivalNature Medicine, 2004
- Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian CancerNew England Journal of Medicine, 2003
- Wortmannin inhibits transcytosis of dimeric IgA by the polymeric immunoglobulin receptorFEBS Letters, 1995
- Selective inhibition of transcytosis by brefeldin A in MDCK cellsCell, 1991